Nele Goeyvaerts
Research Subjects
Nele Goeyvaerts has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Oliver Ackaert
Johnson & Johnson Beerse Belgium
3 shared publications - Thomas Naoki Kakuda
Johnson & Johnson San Diego California USA
3 shared publications - Edward Gane
University of Auckland Auckland New Zealand
2 shared publications Emmanuel Njumbe Ediage
Janssen Research & Development, LLC Beerse Belgium
2 shared publications- Juan Jose Perez Ruixo
Johnson & Johnson Madrid Spain
2 shared publications - Martine Neyens
Johnson & Johnson Beerse Belgium
2 shared publications
Latest Publications
- Open Access
- 9 August 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (5) , 1379-1388
Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV ‐3 in a Controlled Human Infection Model
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM). A combined population pharmacokinetic (PopPK) and viral dynamic model (VDM) was developed to estimate the prophylactic effect of mosnodenvir and to inform dose selection. The PopPK model is a two‐compartment model based on plasma pharmacokinetic data from three Phase I studies and Cohort 1 of the Phase IIa study. Mosnodenvir exposure metrics were estimated for participants receiving high, medium, or low doses. A VDM with an immune response compartment adequately described DENV‐3 RNA profiles for placebo participants and was subsequently extended by including a sigmoid E max relationship with average mosnodenvir concentration at steady state ( C avg,ss ) to capture the antiviral effect on virion production rate. Simulations supported daily and weekly mosnodenvir dosing regimens to further characterize the pharmacokinetic/pharmacodynamic relationship in Cohort 2. Based on the complete Phase IIa study data, the basic reproductive number for DENV‐3 in this CHIM was estimated at 21.7, and the typical C avg,ss required to achieve complete virus eradication was estimated to be 1,410 ng/mL. In conclusion, the combined PopPK and VDM approach effectively informed dose selection and characterized the pharmacokinetic‐antiviral activity relationship, supporting the development of mosnodenvir as a prophylactic treatment for dengue infection.
- 9 August 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (5) , 1379-1388
Open AccessViral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV ‐3 in a Controlled Human Infection Model
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM). A combined population pharmacokinetic (PopPK) and viral dynamic model (VDM) was developed to estimate the prophylactic effect of mosnodenvir and to inform dose selection. The PopPK model is a two‐compartment model based on plasma pharmacokinetic data from three Phase I studies and Cohort 1 of the Phase IIa study. Mosnodenvir exposure metrics were estimated for participants receiving high, medium, or low doses. A VDM with an immune response compartment adequately described DENV‐3 RNA profiles for placebo participants and was subsequently extended by including a sigmoid E max relationship with average mosnodenvir concentration at steady state ( C avg,ss ) to capture the antiviral effect on virion production rate. Simulations supported daily and weekly mosnodenvir dosing regimens to further characterize the pharmacokinetic/pharmacodynamic relationship in Cohort 2. Based on the complete Phase IIa study data, the basic reproductive number for DENV‐3 in this CHIM was estimated at 21.7, and the typical C avg,ss required to achieve complete virus eradication was estimated to be 1,410 ng/mL. In conclusion, the combined PopPK and VDM approach effectively informed dose selection and characterized the pharmacokinetic‐antiviral activity relationship, supporting the development of mosnodenvir as a prophylactic treatment for dengue infection.
- Open Access
- 2 July 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (10) , 3622-3633
Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus
Aims: Canagliflozin was recently approved in type 2 diabetes mellitus (T2DM) patients ≥10 and 24h ) and maximum drug concentration were comparable between paediatric patients and adults for canagliflozin 100‐ or 300‐mg QD. Simulated steady‐state AUC 24h was similar between QD and BID dosing for the same canagliflozin total daily dose in paediatric patients and adults with T2DM. QD to BID bridging was supported by simulated HbA1c and change from baseline in HbA1c in paediatric patients. Conclusions: No canagliflozin dose adjustments are required alone or in combination with metformin to ensure similar plasma exposures between paediatric and adult patients with T2DM, as well as similar HbA1c lowering between QD and BID dosing in paediatric patients.
- 2 July 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (10) , 3622-3633
Open AccessPopulation pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus
Aims: Canagliflozin was recently approved in type 2 diabetes mellitus (T2DM) patients ≥10 and 24h ) and maximum drug concentration were comparable between paediatric patients and adults for canagliflozin 100‐ or 300‐mg QD. Simulated steady‐state AUC 24h was similar between QD and BID dosing for the same canagliflozin total daily dose in paediatric patients and adults with T2DM. QD to BID bridging was supported by simulated HbA1c and change from baseline in HbA1c in paediatric patients. Conclusions: No canagliflozin dose adjustments are required alone or in combination with metformin to ensure similar plasma exposures between paediatric and adult patients with T2DM, as well as similar HbA1c lowering between QD and BID dosing in paediatric patients.
- Open Access
- 10 June 2026
- Published by The Royal Society in Journal of The Royal Society Interface
- Vol. 23 (239)
Estimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infection
Almost half of the world's population is at risk of acquiring dengue virus (DENV) each year. However, no specific licensed prophylactic or antiviral treatment for dengue currently exists. Mosnodenvir, a novel DENV inhibitor, has been shown to inhibit DENV replication in vitro and in animal studies. Here, we provide new insights into the in vivo prophylactic inhibitory effect of mosnodenvir exposure on primary DENV-2 infection by fitting mechanistic within-host models of DENV infection to virological and serological data observed from pre-clinical challenge studies in AG129 mice and rhesus macaques. We estimated a median mosnodenvir concentration achieving 50% of maximal inhibitory effect (IC50) on viral replication of 8.35 (6.82, 9.22) ng ml−1 and 7.61 (5.67, 8.92) ng ml−1 for AG129 mice and rhesus macaques, respectively. A higher concentration is typically required to suppress viral replication in AG129 mice compared with rhesus macaques owing to a higher estimated within-host basic reproduction number (R0) in mice. By integrating multiple data types in a single framework, this study enhances our understanding of the within-host dynamics of primary DENV infection in non-human host species. Furthermore, the methods developed here could possibly assist in quantifying the prophylactic inhibitory effect of mosnodenvir on DENV infections in humans.
- 10 June 2026
- Published by The Royal Society in Journal of The Royal Society Interface
- Vol. 23 (239)
Open AccessEstimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infection
Almost half of the world's population is at risk of acquiring dengue virus (DENV) each year. However, no specific licensed prophylactic or antiviral treatment for dengue currently exists. Mosnodenvir, a novel DENV inhibitor, has been shown to inhibit DENV replication in vitro and in animal studies. Here, we provide new insights into the in vivo prophylactic inhibitory effect of mosnodenvir exposure on primary DENV-2 infection by fitting mechanistic within-host models of DENV infection to virological and serological data observed from pre-clinical challenge studies in AG129 mice and rhesus macaques. We estimated a median mosnodenvir concentration achieving 50% of maximal inhibitory effect (IC50) on viral replication of 8.35 (6.82, 9.22) ng ml−1 and 7.61 (5.67, 8.92) ng ml−1 for AG129 mice and rhesus macaques, respectively. A higher concentration is typically required to suppress viral replication in AG129 mice compared with rhesus macaques owing to a higher estimated within-host basic reproduction number (R0) in mice. By integrating multiple data types in a single framework, this study enhances our understanding of the within-host dynamics of primary DENV infection in non-human host species. Furthermore, the methods developed here could possibly assist in quantifying the prophylactic inhibitory effect of mosnodenvir on DENV infections in humans.
- 15 May 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (6) , 1451-1462
Population Pharmacokinetics of siRNA JNJ ‐73763989 in Healthy Participants and Patients With Chronic Hepatitis B
JNJ‐73763989 is a combination product consisting of two N‐acetylgalactosamine‐conjugated short‐interfering RNA triggers (JNJ‐73763976 and JNJ‐73763924) that are in development as a potential treatment for chronic hepatitis B virus infection. A population pharmacokinetic model for JNJ‐73763989 was developed based on pooled data from seven clinical studies to characterize the plasma pharmacokinetics of the short‐interfering RNAs following subcutaneous administration. Additionally, simulations of liver (target organ) exposure using the final population pharmacokinetic model in conjunction with preclinical information were performed. Disposition of JNJ‐73763976 and JNJ‐73763924 was governed by a linear two‐compartment model describing the peripheral distribution of both short‐interfering RNAs and a saturable component describing liver uptake via the asialoglycoprotein receptor. While the estimated first‐order absorption rate constant was similar for both short‐interfering RNAs, the corresponding absorption half‐life values were 20‐ to 40‐fold longer than the estimated plasma elimination half‐life for both short‐interfering RNAs, indicating absorption rate‐limited or “flip‐flop” kinetics. Plasma‐to‐liver transport of each short‐interfering RNA was modeled by a saturable, receptor‐mediated competitive process, and the affinity for the asialoglycoprotein receptor was 2.5‐fold higher for JNJ‐73763924 relative to JNJ‐73763976. Predicted liver concentrations of both short‐interfering RNA triggers approached steady state after 12 months of JNJ‐73763989 treatment. The 2:1 dosing ratio of JNJ‐73763976 to JNJ‐73763924 was predicted to maintain an ~2:1 liver concentration ratio, irrespective of the identified plasma disposition differences between the triggers. Body weight, creatinine clearance, presence of chronic hepatitis B, and hepatic impairment were associated with plasma pharmacokinetic parameters and were included in the final population pharmacokinetic model.
- 15 May 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (6) , 1451-1462
Population Pharmacokinetics of siRNA JNJ ‐73763989 in Healthy Participants and Patients With Chronic Hepatitis B
JNJ‐73763989 is a combination product consisting of two N‐acetylgalactosamine‐conjugated short‐interfering RNA triggers (JNJ‐73763976 and JNJ‐73763924) that are in development as a potential treatment for chronic hepatitis B virus infection. A population pharmacokinetic model for JNJ‐73763989 was developed based on pooled data from seven clinical studies to characterize the plasma pharmacokinetics of the short‐interfering RNAs following subcutaneous administration. Additionally, simulations of liver (target organ) exposure using the final population pharmacokinetic model in conjunction with preclinical information were performed. Disposition of JNJ‐73763976 and JNJ‐73763924 was governed by a linear two‐compartment model describing the peripheral distribution of both short‐interfering RNAs and a saturable component describing liver uptake via the asialoglycoprotein receptor. While the estimated first‐order absorption rate constant was similar for both short‐interfering RNAs, the corresponding absorption half‐life values were 20‐ to 40‐fold longer than the estimated plasma elimination half‐life for both short‐interfering RNAs, indicating absorption rate‐limited or “flip‐flop” kinetics. Plasma‐to‐liver transport of each short‐interfering RNA was modeled by a saturable, receptor‐mediated competitive process, and the affinity for the asialoglycoprotein receptor was 2.5‐fold higher for JNJ‐73763924 relative to JNJ‐73763976. Predicted liver concentrations of both short‐interfering RNA triggers approached steady state after 12 months of JNJ‐73763989 treatment. The 2:1 dosing ratio of JNJ‐73763976 to JNJ‐73763924 was predicted to maintain an ~2:1 liver concentration ratio, irrespective of the identified plasma disposition differences between the triggers. Body weight, creatinine clearance, presence of chronic hepatitis B, and hepatic impairment were associated with plasma pharmacokinetic parameters and were included in the final population pharmacokinetic model.
- Open Access
- 24 January 2023
- Published by SAGE Publications in Antiviral Therapy
- Vol. 28 (1)
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants
Background: JNJ-4964 is a TLR7 agonist, which, via a type I interferon (IFN)–dependent mechanism, may enhance host immunity suppressed by persistent exposure to hepatitis B antigens in chronic hepatitis B. Methods: PK and PD data were pooled from 2 studies involving 90 participants ( n = 74 JNJ-4964, dose range 0.2–1.8 mg; n = 16 placebo) in a fasted state. Food effects on PK were studied in 24 participants (1.2 or 1.25 mg). A population PK model and PK/PD models were developed to characterize the effect of JNJ-4964 plasma levels on the time course of IFN-α, IFN-γ–inducible protein 10 (IP-10 or CXCL10), IFN-stimulated gene 15 ( ISG15), neopterin and lymphocytes following single and weekly dosing in healthy adults. Covariate effects, circadian rhythms and negative feedback were incorporated in the models. Results: A 3-compartment linear PK model with transit absorption adequately described JNJ-4964 PK. Bioavailability was 44.2% in fed state relative to fasted conditions. Indirect response models with maximum effect (E max ) stimulation on production rate constant (k in ) described IFN-α, IP-10, ISG15 and neopterin, while a precursor-dependent indirect response model with inhibitory effect described the transient lymphocyte reduction. E max , EC 50 and γ (steepness) estimates varied according to PD markers, with EC 50 displaying substantial between-subject variability. Female and Asian race exhibited lower EC 50 , suggesting higher responsiveness. Conclusions: PK/PD models well characterized the time course of immune system markers in healthy adults. Our results supported sex and race as covariates on JNJ-4964 responsiveness, as well as circadian rhythms and negative feedback as homeostatic mechanisms that are relevant in TLR7-induced type I IFN responses.
- 24 January 2023
- Published by SAGE Publications in Antiviral Therapy
- Vol. 28 (1)
Open AccessPopulation pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants
Background: JNJ-4964 is a TLR7 agonist, which, via a type I interferon (IFN)–dependent mechanism, may enhance host immunity suppressed by persistent exposure to hepatitis B antigens in chronic hepatitis B. Methods: PK and PD data were pooled from 2 studies involving 90 participants ( n = 74 JNJ-4964, dose range 0.2–1.8 mg; n = 16 placebo) in a fasted state. Food effects on PK were studied in 24 participants (1.2 or 1.25 mg). A population PK model and PK/PD models were developed to characterize the effect of JNJ-4964 plasma levels on the time course of IFN-α, IFN-γ–inducible protein 10 (IP-10 or CXCL10), IFN-stimulated gene 15 ( ISG15), neopterin and lymphocytes following single and weekly dosing in healthy adults. Covariate effects, circadian rhythms and negative feedback were incorporated in the models. Results: A 3-compartment linear PK model with transit absorption adequately described JNJ-4964 PK. Bioavailability was 44.2% in fed state relative to fasted conditions. Indirect response models with maximum effect (E max ) stimulation on production rate constant (k in ) described IFN-α, IP-10, ISG15 and neopterin, while a precursor-dependent indirect response model with inhibitory effect described the transient lymphocyte reduction. E max , EC 50 and γ (steepness) estimates varied according to PD markers, with EC 50 displaying substantial between-subject variability. Female and Asian race exhibited lower EC 50 , suggesting higher responsiveness. Conclusions: PK/PD models well characterized the time course of immune system markers in healthy adults. Our results supported sex and race as covariates on JNJ-4964 responsiveness, as well as circadian rhythms and negative feedback as homeostatic mechanisms that are relevant in TLR7-induced type I IFN responses.
- Open Access
- 11 June 2022
- Published by SAGE Publications in Antiviral Therapy
- Vol. 27 (3)
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B
Background: JNJ-73763989 comprises two hepatitis B virus (HBV)-specific, liver-targeted N-galactosamine-conjugated short interfering RNA triggers, JNJ-73763976 and JNJ-73763924. JNJ-73763989 pharmacokinetics, safety and tolerability were assessed in two phase 1 studies: Japanese (NCT04002752), and non-Japanese healthy participants and chronic hepatitis B (CHB) patients also receiving the HBV capsid assembly modulator JNJ-56136379 and a nucleos(t)ide analogue (NA) (NCT03365947). Methods: Healthy participant cohorts were double-blind and randomized to receive a single subcutaneous JNJ-73763989 dose (non-Japanese participants, 35, 100, 200, 300 or 400 mg; Japanese participants, 25, 100 or 200 mg) or placebo. JNJ-73763976 and JNJ-73763924 plasma concentrations were assessed over 48 h. CHB patients received JNJ-73763989 200 mg every 4 weeks plus daily oral JNJ-56136379 250 mg and NA in an open-label fashion. Safety and tolerability were assessed through Day 28 (healthy participants) or Day 112 (patients). Results: Thirty non-Japanese ( n = 4/dose; placebo, n = 10) and 24 Japanese healthy participants ( n = 6/dose; placebo, n = 6) were randomized. JNJ-73763976 and JNJ-73763924 exposure generally increased in a dose-proportional manner. Mean plasma half-life was 4–9 h. No differences between pharmacokinetic parameters were apparent between non-Japanese and Japanese healthy participants. In the 12 CHB patients, mean JNJ-73763976, JNJ-73763924 and JNJ-56136379 plasma concentrations 2 h post-dose on Day 29 were 663, 269 and 14,718 ng/mL, respectively. In both studies, all adverse events were mild/moderate. Conclusion: JNJ-73763976 and JNJ-73763924 had short plasma half-lives and exposure generally increased in a dose-proportional manner; there were no pharmacokinetic differences between Japanese and non-Japanese healthy adults. JNJ-73763989 with or without JNJ-56136379 and NA was generally safe and well tolerated.
- 11 June 2022
- Published by SAGE Publications in Antiviral Therapy
- Vol. 27 (3)
Open AccessJNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B
Background: JNJ-73763989 comprises two hepatitis B virus (HBV)-specific, liver-targeted N-galactosamine-conjugated short interfering RNA triggers, JNJ-73763976 and JNJ-73763924. JNJ-73763989 pharmacokinetics, safety and tolerability were assessed in two phase 1 studies: Japanese (NCT04002752), and non-Japanese healthy participants and chronic hepatitis B (CHB) patients also receiving the HBV capsid assembly modulator JNJ-56136379 and a nucleos(t)ide analogue (NA) (NCT03365947). Methods: Healthy participant cohorts were double-blind and randomized to receive a single subcutaneous JNJ-73763989 dose (non-Japanese participants, 35, 100, 200, 300 or 400 mg; Japanese participants, 25, 100 or 200 mg) or placebo. JNJ-73763976 and JNJ-73763924 plasma concentrations were assessed over 48 h. CHB patients received JNJ-73763989 200 mg every 4 weeks plus daily oral JNJ-56136379 250 mg and NA in an open-label fashion. Safety and tolerability were assessed through Day 28 (healthy participants) or Day 112 (patients). Results: Thirty non-Japanese ( n = 4/dose; placebo, n = 10) and 24 Japanese healthy participants ( n = 6/dose; placebo, n = 6) were randomized. JNJ-73763976 and JNJ-73763924 exposure generally increased in a dose-proportional manner. Mean plasma half-life was 4–9 h. No differences between pharmacokinetic parameters were apparent between non-Japanese and Japanese healthy participants. In the 12 CHB patients, mean JNJ-73763976, JNJ-73763924 and JNJ-56136379 plasma concentrations 2 h post-dose on Day 29 were 663, 269 and 14,718 ng/mL, respectively. In both studies, all adverse events were mild/moderate. Conclusion: JNJ-73763976 and JNJ-73763924 had short plasma half-lives and exposure generally increased in a dose-proportional manner; there were no pharmacokinetic differences between Japanese and non-Japanese healthy adults. JNJ-73763989 with or without JNJ-56136379 and NA was generally safe and well tolerated.